Key result
Baseline Framingham risk score did not significantly predict an increase in future ECG-derived QRS duration over an average of 3.3 years (OR 1.04).
Why the study?
Prolonged ECG QRS duration is associated with increased cardiovascular risk, but it is unclear whether the Framingham risk score predicts baseline or short-term changes in QRS duration.
Does baseline Framingham risk score predict future changes in ECG-derived QRS duration in a community cohort without pre-existing cardiovascular disease?
Cross-Sectional (n=202)
No
Does baseline Framingham risk score predict future changes in ECG-derived QRS duration in a community cohort without pre-existing cardiovascular disease?
Odds Ratio: 1.04 (95% CI 0.98–1.1)
p-value: p=0.230
Baseline Framingham risk score does not predict short-term worsening of QRS duration, although higher cross-sectional scores are weakly associated with longer QRS duration.
Baseline Framingham score does not predict short-term QRS changes; leaves open whether longer follow-up reveals links to conduction delay.
Background Prolonged electrocardiogram (ECG) QRS duration has been associated with increased cardiovascular risk. It is unclear whether the main predictor of cardiovascular risk, the Framingham risk score also predicts short-term changes in ECG QRS duration. Our aim is to determine whether baseline Framingham risk score is associated with baseline or changes in QRS duration. Methods A retrospective cross-sectional analysis was performed using observational data obtained from two hundred two participants. Framingham risk score was calculated using an online risk calculator. QRS duration was obtained using a 10 s trace from a Welch Allyn PC-based 12-lead ECG system. Results Average follow-up duration was 3.3 ± 1.1 years. Mean QRS change was 1.8 ± 11.4 ms. Specifically, among two hundred two participants, there are 104 subjects with a greater QRS duration at follow-up, while 98 subjects had the same or a shorter follow-up QRS duration. Baseline Framingham risk score did not significantly predict an increase in QRSd with an odds ratio of 1.04 (P = 0.230). Regression analysis of QRS duration at baseline and Framingham risk at baseline had a weak association (R2 = 0.020; P = 0.043). The Framingham risk score at follow-up was likewise has a weak association with follow-up QRS duration (R2 = 0.045; P = 0.002). Conclusions Our results do not demonstrate a statistically significant association between Framingham risk parameters and future QRS duration changes over longitudinal time. QRS duration had variable changes between baseline and follow-up. This might suggest that a longer period of follow-up is required to document more stable increases in QRS duration associated with ventricular pathology. A larger population study is needed to confirm our observations.
No takes yet. Share an insight, caveat, or question.
Stone et al. (2020) conducted a cross-sectional in Cardiovascular risk (n=202). Baseline Framingham risk score was evaluated on Increase in QRS duration at follow-up (OR 1.04, 95% CI 0.98, 1.10, p=0.230). Baseline Framingham risk score did not significantly predict an increase in future ECG-derived QRS duration over an average of 3.3 years (OR 1.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: